Neoadjuvant and Adjuvant Therapy

Core Concepts & Aims - Setting the Stage

• Neoadjuvant Therapy (NAT): Systemic or local therapy administered before definitive surgery.
  • Aims: Downstage tumor, improve resectability, assess biological response, early micrometastasis control.
• Adjuvant Therapy (AT): Systemic or local therapy administered after definitive surgery.
  • Aims: Eradicate residual micrometastases, reduce recurrence risk, improve overall survival.
• Perioperative Therapy: Treatment strategy involving therapy both before and after surgery, aiming for comprehensive tumor control.

⭐ Neoadjuvant therapy provides a unique opportunity for in-vivo assessment of tumor sensitivity to specific treatments, guiding further management strategies.

Neoadjuvant Approach - Shrink Smart

Administered before definitive surgery.

• Goal: Shrink tumor (downstage), ↑ resectability, early micrometastasis control.
• Key Indications:
  • Locally advanced tumors (e.g., breast, rectal, esophageal, H&N, sarcoma).
  • Borderline resectable cases.
  • Organ preservation (e.g., breast, larynx, rectal sphincter).
• Advantages:
  • Assesses in vivo chemo/radio-sensitivity.
  • ↑ R0 resection rates.
  • Enables less radical surgery.
• Disadvantages:
  • Surgery delay.
  • Treatment toxicity.
  • Rare risk of progression.
• Modalities: Chemo (NACT), Radio (NART), CRT, Hormonal, Targeted, Immuno.

⭐ Pathological Complete Response (pCR) post-neoadjuvant therapy is a strong prognostic indicator in many cancers like breast and rectal.

Adjuvant Approach - Safety Net Strategy

• Therapy after surgery; targets micrometastases to ↓ recurrence & ↑ survival.
• Key Rationale: "Safety net" post-primary tumor removal.
• Indications:
  • High-risk pathology: positive margins, nodal spread (e.g., pN+), high grade.
  • Certain cancers (e.g., breast, colorectal, lung).
• Modalities: Chemotherapy (CTX), Radiotherapy (XRT), Hormonal, Targeted, Immunotherapy.
• Pros: Addresses occult disease; pathology-informed.
• Cons: Overtreatment risk; toxicity; potential delay.

⭐ Adjuvant therapy in Stage III colon cancer or HER2+ breast cancer is a standard of care, significantly boosting cure rates post-surgery.

Comparative Analysis - Tale of Two Timings

Tumour-Specific Protocols - Real-World Tactics

• Breast Cancer:
  • Neoadjuvant: For downstaging (e.g., LABC), HER2+ (TCHP), TNBC (AC-T ± Pembrolizumab).
  • Adjuvant: Based on receptor status & risk (e.g., Endocrine Tx, Trastuzumab, Chemo).
• Colorectal Cancer (CRC):
  • Rectal (locally advanced): Neoadjuvant Chemoradiotherapy (CRT) (e.g., Capecitabine/5-FU + RT) is standard.
  • Colon (Stage III, high-risk Stage II): Adjuvant FOLFOX or CAPOX.
• Esophageal/Gastric Cancer:
  • Adenocarcinoma (Gastric/Esophageal): Perioperative FLOT (5-FU, Leucovorin, Oxaliplatin, Docetaxel).
  • Esophageal SCC: Neoadjuvant CRT (CROSS protocol: Carboplatin/Paclitaxel + RT) or definitive CRT.
• Soft Tissue Sarcomas (High-Risk):
  • Neoadjuvant RT ± Chemo (e.g., Doxorubicin/Ifosfamide) for limb preservation, large/deep tumours. Adjuvant if upfront surgery.

⭐ For locally advanced rectal cancer, neoadjuvant chemoradiotherapy (CRT) followed by Total Mesorectal Excision (TME) is the standard of care, significantly improving local control and sphincter preservation rates.

High‑Yield Points - ⚡ Biggest Takeaways

• Neoadjuvant therapy: given before surgery to downstage tumors, improving resectability.
• Adjuvant therapy: given after surgery to target micrometastases, reducing recurrence.
• Modalities: chemotherapy, radiotherapy, hormone therapy, immunotherapy, targeted therapy.
• Indications vary by tumor type, stage, grade, and patient factors.
• Response assessment (e.g., RECIST for neoadjuvant) guides further treatment.
• Timing: Adjuvant therapy usually starts 4-6 weeks post-surgery.
• Goals: Improve disease-free survival (DFS) and overall survival (OS).